Trials / Completed
CompletedNCT02466867
An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis
An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Merz North America, Inc. · Industry
- Sex
- All
- Age
- 2 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-center, multi-application pharmacokinetic study in pediatric subjects with tinea corporis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naftin® Cream, 2% (younger pediatric cohort) | Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months. |
| DRUG | Naftin® Cream, 2% (older pediatric cohort) | Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months. |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-10-01
- Completion
- 2015-12-01
- First posted
- 2015-06-09
- Last updated
- 2016-10-28
Locations
3 sites across 3 countries: United States, Dominican Republic, Honduras
Source: ClinicalTrials.gov record NCT02466867. Inclusion in this directory is not an endorsement.